Neurocrine Biosciences Insider Sold Shares Worth $9,197,550, According to a Recent SEC Filing
Neurocrine Biosciences(NBIX.US) Officer Sells US$9.2 Million in Common Stock
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Neurocrine Biosciences To Present At J.P. Morgan Healthcare Conference; Webcast At 11:15 AM ET
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Positive Growth Prospects for Neurocrine Biosciences Driven by Crenessity Launch and Strategic Patient Accessibility Initiatives
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50
Srav Reddy : You missed VSTM and